Tuesday, December 31, 2024

Tirzepatide Outperforms Semaglutide in Weight Loss: SURMOUNT-5 Study Results

Tirzepatide demonstrated superior weight loss efficacy compared to semaglutide in the SURMOUNT-5 trial, according to topline results released by Eli Lilly. (Learn More)

The 72-week study involved 751 patients with obesity or overweight and at least one weight-related comorbidity.

Tirzepatide users experienced an average 20.2% reduction in body weight, while semaglutide users achieved a 13.7% reduction.

This represents a 47% greater weight loss with tirzepatide compared to semaglutide.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, while semaglutide is solely a GLP-1 receptor agonist.

Over 31% of tirzepatide patients achieved a 25% reduction in body weight, compared to 16.1% of semaglutide patients.

Both drugs primarily caused mild-to-moderate gastrointestinal issues as side effects.

Tirzepatide (Zepbound) and semaglutide (Wegovy) are both FDA-approved for chronic weight management in adults with obesity or overweight and a weight-related condition.

Semaglutide has an additional indication for cardiovascular disease prevention based on the SELECT trial.

Both drugs are also approved under different names (Mounjaro and Ozempic, respectively) for type 2 diabetes treatment.

SUMMIT and STEP-HFpEF trials have shown the effectiveness of tirzepatide and semaglutide in patients with heart failure with preserved ejection (HFpEF).

Eli Lilly is conducting the SURPASS-CVOT study, comparing tirzepatide and dulaglutide in patients with type 2 diabetes.

Full SURMOUNT-5 results are expected to be published and presented at a major medical meeting in 2025.

Key Takeaways:

  • Tirzepatide showed 47% greater weight loss than semaglutide over 72 weeks
  • Tirzepatide users lost an average of 20.2% body weight vs 13.7% with semaglutide
  • Both drugs are FDA-approved for chronic weight management and type 2 diabetes treatment
  • Full SURMOUNT-5 results are anticipated in 2025

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.